Semintra 4 mg/mL Oral Solution 4 mg Solution is a Health Canada–registered veterinary drug (DIN 02418126) held by Boehringer Ingelheim Animal Health Canada Inc., containing Telmisartan. Health Canada lists its status as Marketed (status date 17 Mar 2020). Nexara Health has matched 1125 registrations of Telmisartan across 38 other regulated markets.

Health Canada registration

Telmisartan registered in other markets

1125 registrations of the same molecule in 38 national registries outside Canada (first 120 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.

See every manufacturer of Telmisartan worldwide →

Regulator price references for Telmisartan

Published list or reimbursement prices for Telmisartan presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.

Sourcing through Nexara Health

Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.

Frequently asked questions

Is Semintra 4 mg/mL Oral Solution (DIN 02418126) marketed in Canada?

Yes. Health Canada lists DIN 02418126 as Marketed as of 17 Mar 2020.

Who holds the Canadian licence for this product?

Boehringer Ingelheim Animal Health Canada Inc. is the company of record in the Health Canada Drug Product Database.

Is Telmisartan registered outside Canada?

Yes — Nexara Health has matched 1125 registrations in 38 other markets (see the table above).

Where does this data come from?

Health Canada Drug Product Database (DPD), DIN 02418126, status date 2020-03-17; national medicine registries: AIFA liste A/H, BDA, CNS liste positive, DH Drug Office, eEKO (Erstattungskodex), EMA centrally authorised, Fimea Perusrekisteri, HPRA, HZZO, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, MISPAS, MoH deltio timwn, NEAK PUPHA, NHRA, PAMI, PBS, SUKL DLP; price sources: EDE, eEKO (Erstattungskodex), MoH deltio timwn, NEAK PUPHA, NHRA, PBS. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.

Source: Health Canada Drug Product Database (DPD), DIN 02418126, status date 2020-03-17; national medicine registries: AIFA liste A/H, BDA, CNS liste positive, DH Drug Office, eEKO (Erstattungskodex), EMA centrally authorised, Fimea Perusrekisteri, HPRA, HZZO, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, MISPAS, MoH deltio timwn, NEAK PUPHA, NHRA, PAMI, PBS, SUKL DLP; price sources: EDE, eEKO (Erstattungskodex), MoH deltio timwn, NEAK PUPHA, NHRA, PBS.

Health Canada Drug Product Database (DPD), DIN 02418126, status date 2020-03-17; national medicine registries: AIFA liste A/H, BDA, CNS liste positive, DH Drug Office, eEKO (Erstattungskodex), EMA centrally authorised, Fimea Perusrekisteri, HPRA, HZZO, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, MISPAS, MoH deltio timwn, NEAK PUPHA, NHRA, PAMI, PBS, SUKL DLP; price sources: EDE, eEKO (Erstattungskodex), MoH deltio timwn, NEAK PUPHA, NHRA, PBS. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.